These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


764 related items for PubMed ID: 27836820

  • 1. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis.
    Ozen G, Pedro S, Holmqvist ME, Avery M, Wolfe F, Michaud K.
    Ann Rheum Dis; 2017 May; 76(5):848-854. PubMed ID: 27836820
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis.
    Lillegraven S, Greenberg JD, Reed GW, Saunders K, Curtis JR, Harrold L, Hochberg MC, Pappas DA, Kremer JM, Solomon DH.
    PLoS One; 2019 May; 14(1):e0210459. PubMed ID: 30673733
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Risk of venous thromboembolism in patients with rheumatoid arthritis: initiating disease-modifying antirheumatic drugs.
    Kim SC, Solomon DH, Liu J, Franklin JM, Glynn RJ, Schneeweiss S.
    Am J Med; 2015 May; 128(5):539.e7-17. PubMed ID: 25534420
    [Abstract] [Full Text] [Related]

  • 6. Sex-associated Treatment Differences and Their Outcomes in Rheumatoid Arthritis: Results from the METEOR Register.
    Bergstra SA, Allaart CF, Ramiro S, Chopra A, Govind N, Silva C, Murphy EA, Landewé RBM.
    J Rheumatol; 2018 Oct; 45(10):1361-1366. PubMed ID: 29907672
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study.
    Ozen G, Pedro S, Schumacher R, Simon TA, Michaud K.
    Arthritis Res Ther; 2019 Jun 07; 21(1):141. PubMed ID: 31174592
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use.
    Proudman SM, Keen HI, Stamp LK, Lee AT, Goldblatt F, Ayres OC, Rischmueller M, James MJ, Hill CL, Caughey GE, Cleland LG.
    Semin Arthritis Rheum; 2007 Oct 07; 37(2):99-111. PubMed ID: 17391739
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Disease-modifying treatment for inflammatory rheumatism in sub-Saharan Africa: outcome at 6 months of 205 Senegalese patients with rheumatoid arthritis].
    Ndongo S, Pouye A, Lekpa FK, Bihéhé DM, Tiendrebeogo J, Ndao AC, Ka MM, Moreira Diop T.
    Med Sante Trop; 2012 Oct 07; 22(4):385-9. PubMed ID: 23352953
    [Abstract] [Full Text] [Related]

  • 20. Concomitant methotrexate and tacrolimus augment the clinical response to abatacept in patients with rheumatoid arthritis with a prior history of biological DMARD use.
    Takahashi N, Fujibayashi T, Kida D, Hirano Y, Kato T, Kato D, Saito K, Kaneko A, Yabe Y, Takagi H, Oguchi T, Miyake H, Watanabe T, Hayashi M, Kanayama Y, Funahashi K, Hanabayashi M, Hirabara S, Asai S, Takemoto T, Terabe K, Asai N, Yoshioka Y, Ishiguro N, Kojima T.
    Rheumatol Int; 2015 Oct 07; 35(10):1707-16. PubMed ID: 25991396
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 39.